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Background: We have previously shown that recombinant human interleukin-11 (rhIL-11) treatment leads to in vivo mobilization of CD34+/
VEGFR2+ mononuclear cells (with endothelial progenitor cell properties) in vivo. However, the clinical utility of rhIL-11 on reperfusion after arterial 
occlusion is currently unknown.
Methods: We pretreated Sv129 mice with 200μg/kg/day of rhIL-11 or placebo for 72 hours prior to femoral artery ligation and performed laser 
Doppler perfusion imaging pre-operatively and at several time points after femoral artery ligation. We analyzed mononuclear cells in the peripheral 
blood and tissues and performed immunohistochemical analysis of muscle tissues distal to the site of occlusion.
Results: Recombinant human interleukin-11 treatment resulted in 3-fold increase in plantar collateral vessel perfusion and 4-fold increase in 
collateral vessel growth (increase in luminal diameter) which correlated with a significant increase in hindlimb function measured by hindlimb 
appearance- and hindlimb use-score. There was a significant increase in both circulating and peri-collateral vessel CD34+/VEGFR2+ mononuclear 
cells and monocytes in rhIL-11-treated mice when compared with syngeneic mice treated with placebo under the same experimental condition.
Conclusions: Recombinant human interleukin-11 treatment augments collateral vessel reperfusion, blood flow recovery, collateral vessel growth 
and hindlimb functional recovery after femoral artery occlusion suggesting a potential role of rhIL-11 on the treatment of patients with peripheral 
vascular disease.
